{"id":4284,"date":"2021-07-12T10:58:48","date_gmt":"2021-07-12T10:58:48","guid":{"rendered":"https:\/\/www.saince.com\/?p=4284"},"modified":"2023-04-28T09:41:45","modified_gmt":"2023-04-28T13:41:45","slug":"fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer","status":"publish","type":"post","link":"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/","title":{"rendered":"FDA approves first PSMA PET imaging agent for prostate cancer"},"content":{"rendered":"<p dir=\"ltr\"><span style=\"font-weight: 400\">US FDA approves the <strong>Piflufolastat F-18<\/strong><\/span><span style=\"font-weight: 400\">\u00a0injection for prostate cancer detection It is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA commercially available PSMA PET imaging agent. It allows doctors to see suspected prostate cancer at an early stage. <\/span><\/p>\n<p dir=\"ltr\"><span style=\"font-weight: 400\">This is a highly effective imaging approach to detect the spread of cancer to other parts of the body.<\/span><\/p>\n<p dir=\"ltr\"><span style=\"font-weight: 400\">Read the full article:\u00a0<\/span><\/p>\n<p dir=\"ltr\"><a href=\"https:\/\/www.itnonline.com\/content\/fda-approves-first-commercially-available-psma-pet-imaging-agent-prostate-cancer\"><span style=\"font-weight: 400\">https:\/\/www.itnonline.com\/content\/fda-approves-first-commercially-available-psma-pet-imaging-agent-prostate-cancer<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>US FDA approves the Piflufolastat F-18\u00a0injection for prostate cancer detection It is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA commercially available PSMA PET imaging agent. It allows doctors to see suspected prostate cancer at an early stage. This is a highly effective imaging approach to detect the spread of cancer [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[],"class_list":["post-4284","post","type-post","status-publish","format-standard","hentry","category-radiology-updates"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.13 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FDA approves first PSMA PET imaging agent for prostate cancer -<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA approves first PSMA PET imaging agent for prostate cancer -\" \/>\n<meta property=\"og:description\" content=\"US FDA approves the Piflufolastat F-18\u00a0injection for prostate cancer detection It is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA commercially available PSMA PET imaging agent. It allows doctors to see suspected prostate cancer at an early stage. This is a highly effective imaging approach to detect the spread of cancer [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-12T10:58:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-28T13:41:45+00:00\" \/>\n<meta name=\"author\" content=\"Raghu Vir\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Raghu Vir\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/\"},\"author\":{\"name\":\"Raghu Vir\",\"@id\":\"https:\/\/www.saince.com\/blog\/#\/schema\/person\/1f2d35babed92cc8da140a1e8098cc10\"},\"headline\":\"FDA approves first PSMA PET imaging agent for prostate cancer\",\"datePublished\":\"2021-07-12T10:58:48+00:00\",\"dateModified\":\"2023-04-28T13:41:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/\"},\"wordCount\":82,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.saince.com\/blog\/#organization\"},\"articleSection\":[\"Radiology Updates\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/\",\"url\":\"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/\",\"name\":\"FDA approves first PSMA PET imaging agent for prostate cancer -\",\"isPartOf\":{\"@id\":\"https:\/\/www.saince.com\/blog\/#website\"},\"datePublished\":\"2021-07-12T10:58:48+00:00\",\"dateModified\":\"2023-04-28T13:41:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.saince.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA approves first PSMA PET imaging agent for prostate cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.saince.com\/blog\/#website\",\"url\":\"https:\/\/www.saince.com\/blog\/\",\"name\":\"https:\/\/www.saince.com\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.saince.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.saince.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.saince.com\/blog\/#organization\",\"name\":\"Saince, Inc.\",\"url\":\"https:\/\/www.saince.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.saince.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.saince.com\/blog\/wp-content\/uploads\/2022\/11\/logo.png\",\"contentUrl\":\"https:\/\/www.saince.com\/blog\/wp-content\/uploads\/2022\/11\/logo.png\",\"width\":177,\"height\":50,\"caption\":\"Saince, Inc.\"},\"image\":{\"@id\":\"https:\/\/www.saince.com\/blog\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.saince.com\/blog\/#\/schema\/person\/1f2d35babed92cc8da140a1e8098cc10\",\"name\":\"Raghu Vir\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.saince.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b86bb9fa0a2c418a075287e457916b047d92fa95e18ae97c28b6be424e9ba817?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b86bb9fa0a2c418a075287e457916b047d92fa95e18ae97c28b6be424e9ba817?s=96&d=mm&r=g\",\"caption\":\"Raghu Vir\"},\"url\":\"https:\/\/www.saince.com\/blog\/author\/raghuvir\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA approves first PSMA PET imaging agent for prostate cancer -","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/","og_locale":"en_GB","og_type":"article","og_title":"FDA approves first PSMA PET imaging agent for prostate cancer -","og_description":"US FDA approves the Piflufolastat F-18\u00a0injection for prostate cancer detection It is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA commercially available PSMA PET imaging agent. It allows doctors to see suspected prostate cancer at an early stage. This is a highly effective imaging approach to detect the spread of cancer [&hellip;]","og_url":"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/","article_published_time":"2021-07-12T10:58:48+00:00","article_modified_time":"2023-04-28T13:41:45+00:00","author":"Raghu Vir","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Raghu Vir"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/#article","isPartOf":{"@id":"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/"},"author":{"name":"Raghu Vir","@id":"https:\/\/www.saince.com\/blog\/#\/schema\/person\/1f2d35babed92cc8da140a1e8098cc10"},"headline":"FDA approves first PSMA PET imaging agent for prostate cancer","datePublished":"2021-07-12T10:58:48+00:00","dateModified":"2023-04-28T13:41:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/"},"wordCount":82,"commentCount":0,"publisher":{"@id":"https:\/\/www.saince.com\/blog\/#organization"},"articleSection":["Radiology Updates"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/","url":"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/","name":"FDA approves first PSMA PET imaging agent for prostate cancer -","isPartOf":{"@id":"https:\/\/www.saince.com\/blog\/#website"},"datePublished":"2021-07-12T10:58:48+00:00","dateModified":"2023-04-28T13:41:45+00:00","breadcrumb":{"@id":"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.saince.com\/blog\/fda-approves-first-psma-pet-imaging-agent-for-prostate-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.saince.com\/blog\/"},{"@type":"ListItem","position":2,"name":"FDA approves first PSMA PET imaging agent for prostate cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.saince.com\/blog\/#website","url":"https:\/\/www.saince.com\/blog\/","name":"https:\/\/www.saince.com","description":"","publisher":{"@id":"https:\/\/www.saince.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.saince.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.saince.com\/blog\/#organization","name":"Saince, Inc.","url":"https:\/\/www.saince.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.saince.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.saince.com\/blog\/wp-content\/uploads\/2022\/11\/logo.png","contentUrl":"https:\/\/www.saince.com\/blog\/wp-content\/uploads\/2022\/11\/logo.png","width":177,"height":50,"caption":"Saince, Inc."},"image":{"@id":"https:\/\/www.saince.com\/blog\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.saince.com\/blog\/#\/schema\/person\/1f2d35babed92cc8da140a1e8098cc10","name":"Raghu Vir","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.saince.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b86bb9fa0a2c418a075287e457916b047d92fa95e18ae97c28b6be424e9ba817?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b86bb9fa0a2c418a075287e457916b047d92fa95e18ae97c28b6be424e9ba817?s=96&d=mm&r=g","caption":"Raghu Vir"},"url":"https:\/\/www.saince.com\/blog\/author\/raghuvir\/"}]}},"_links":{"self":[{"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/posts\/4284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/comments?post=4284"}],"version-history":[{"count":1,"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/posts\/4284\/revisions"}],"predecessor-version":[{"id":4753,"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/posts\/4284\/revisions\/4753"}],"wp:attachment":[{"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/media?parent=4284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/categories?post=4284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.saince.com\/blog\/wp-json\/wp\/v2\/tags?post=4284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}